APLS
HEALTHCAREApellis Pharmaceuticals Inc
$41.12+0.15 (+0.37%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving APLS Today?
No stock-specific AI insight has been generated for APLS yet. However, APLS was mentioned in the following AI insights:
52-Week Range
$16.10$41.14
$41.12
Fundamentals
Market Cap$5.3B
P/E Ratio228.4
EPS$0.18
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.0%
Debt / Equity—
Trading
Volume3.7M
Avg Volume (10D)—
Shares Outstanding128.0M
APLS News
23 articles- Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600Yahoo Finance·May 7, 2026
- Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key MetricsYahoo Finance·May 7, 2026
- Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue EstimatesYahoo Finance·May 7, 2026
- ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Should You Buy?Yahoo Finance·May 1, 2026
- Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Should You Buy?Yahoo Finance·Apr 29, 2026
- Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?Yahoo Finance·Apr 24, 2026
- OCGN's Gene-Agnostic Strategy Could Reset Retinal TherapyYahoo Finance·Apr 22, 2026
- Biogen Expands Targeted Therapy Pipeline With Apellis Deal And Alloy AllianceYahoo Finance·Apr 19, 2026
- Tesla upgraded, AppLovin initiated: Wall Street's top analyst callsYahoo Finance·Apr 14, 2026
- Gilead Expands Oncology Pipeline With $5B Tubulis DealYahoo Finance·Apr 9, 2026
- Biogen Taps Alloy Platform To Push Antisense Drug Pipeline ForwardBenzinga·Apr 7, 2026
- Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation StoryYahoo Finance·Apr 4, 2026
- Where the New Houses Are—and What That Says About GrowthYahoo Finance·Apr 3, 2026
- Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers BankruptcyBenzinga·Apr 3, 2026
- Here Are Thursday’s Top Wall Street Analyst Research Calls: Akamai Technologies, Astra-Zeneca, Brinker, e.l.f. Beauty, Freeport-McMoran, Vale, Wingstop, Wix.com, and More247 Wall St·Apr 2, 2026
- How The Apellis Pharmaceuticals (APLS) Investment Story Is Shifting With New Deals And Analyst RevisionsYahoo Finance·Apr 1, 2026
- Biogen to Acquire Apellis for $5.6B to Strengthen Immunology PortfolioYahoo Finance·Apr 1, 2026
- Disney upgraded, Nike downgraded: Wall Street's top analyst callsYahoo Finance·Apr 1, 2026
- Here Are Wednesday’s Top Wall Street Analyst Research Calls: Boeing, Datadog, Disney, Formula One Group, Nike, Rivian, Rocket Lab, ServiceNow, and More247 Wall St·Apr 1, 2026
- Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last?Yahoo Finance·Apr 1, 2026
- Biogen uplifts rare disease pipeline with $5.6bn Apellis buyoutPharmaceutical-technology·Apr 1, 2026
- Apellis Pharmaceuticals (APLS) Hits 2-Year High on 140% Upside from Biogen MergerYahoo Finance·Apr 1, 2026
- Biogen Lands Two Fast-Growing Drugs In Blockbuster Apellis DealBenzinga·Mar 31, 2026
All 23 articles loaded
Price Data
Open$0.00
Previous Close$40.97
Day High$0.00
Day Low$0.00
52 Week High$41.14
52 Week Low$16.10
52-Week Range
$16.10$41.14
$41.12
Fundamentals
Market Cap$5.3B
P/E Ratio228.4
EPS$0.18
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.0%
Debt / Equity—
Trading
Volume3.7M
Avg Volume (10D)—
Shares Outstanding128.0M
About Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—